Development of SARS vaccines and therapeutics is still needed.
作者信息
Jiang Shibo, Lu Lu, Du Lanying
机构信息
Key Laboratory of Medical Molecular Virology of Ministries of Education & Health, Shanghai Medical College & Institute of Medical Microbiology, Fudan University, Shanghai 200032, China.
The Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10065, USA.
出版信息
Future Virol. 2013 Jan;8(1):1-2. doi: 10.2217/fvl.12.126. Epub 2012 Dec 20.
Abstract
摘要
相似文献
1
Development of SARS vaccines and therapeutics is still needed.仍然需要研发非典疫苗和治疗方法。
Future Virol. 2013 Jan;8(1):1-2. doi: 10.2217/fvl.12.126. Epub 2012 Dec 20.
2
Specific serology for emerging human coronaviruses by protein microarray.基于蛋白质微阵列的新兴人类冠状病毒的特异性血清学研究。
Euro Surveill. 2013 Apr 4;18(14):20441. doi: 10.2807/1560-7917.es2013.18.14.20441.
3
Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5.新型人类C组β冠状病毒与中菊头蝠冠状病毒HKU4及伏翼蝠冠状病毒HKU5的遗传相关性。
Emerg Microbes Infect. 2012 Nov;1(11):e35. doi: 10.1038/emi.2012.45. Epub 2012 Nov 7.
4
Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors.人类冠状病毒229E和NL63刺突蛋白内的高度保守区域决定了它们对各自细胞受体的识别。
J Virol. 2006 Sep;80(17):8639-52. doi: 10.1128/JVI.00560-06.
5
Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.确定控制IFITM蛋白对人冠状病毒进入的限制与增强活性的残基。
J Virol. 2018 Feb 26;92(6). doi: 10.1128/JVI.01535-17. Print 2018 Mar 15.
引用本文的文献
1
Immune Response to SARS-CoV-2 Vaccines.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的免疫反应
Biomedicines. 2022 Jun 21;10(7):1464. doi: 10.3390/biomedicines10071464.
2
The Coronavirus pandemic - 2022: Viruses, variants & vaccines.2022年冠状病毒大流行：病毒、变种与疫苗
Cytokine Growth Factor Rev. 2022 Feb;63:1-9. doi: 10.1016/j.cytogfr.2022.02.002. Epub 2022 Feb 12.
3
Viral Pandemics in the Past Two Decades: An Overview.过去二十年中的病毒性大流行：概述
J Family Med Prim Care. 2021 Aug;10(8):2745-2750. doi: 10.4103/jfmpc.jfmpc_2071_20. Epub 2021 Aug 27.
4
Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19.冠状病毒爆发的荟萃分析和综合研究：SARS、MERS 和 COVID-19。
J Infect Public Health. 2021 Aug;14(8):1051-1064. doi: 10.1016/j.jiph.2021.06.007. Epub 2021 Jun 17.
5
Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses.全面比较 SARS-CoV-2、SARS-CoV 和 MERS-CoV 感染的 RNA-Seq 数据：替代进入途径和先天免疫反应。
Front Immunol. 2021 May 28;12:656433. doi: 10.3389/fimmu.2021.656433. eCollection 2021.
6
Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.冠状病毒（SARS-CoV-2）：潜在疫苗的系统评价。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1865774. doi: 10.1080/21645515.2020.1865774. Epub 2021 Feb 5.
7
Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment.2019冠状病毒病大流行的现状；特征、诊断、预防及治疗
J Res Med Sci. 2020 Nov 3;25:101. doi: 10.4103/jrms.JRMS_476_20. eCollection 2020.
8
Adjuvants for Coronavirus Vaccines.冠状病毒疫苗佐剂。
Front Immunol. 2020 Nov 6;11:589833. doi: 10.3389/fimmu.2020.589833. eCollection 2020.
9
Surging publications on the COVID-19 pandemic.关于新冠疫情的出版物激增。
Clin Microbiol Infect. 2021 Mar;27(3):484-486. doi: 10.1016/j.cmi.2020.09.010. Epub 2020 Sep 22.
10
Potential strategies for combating COVID-19.应对 COVID-19 的潜在策略。
Arch Virol. 2020 Nov;165(11):2419-2438. doi: 10.1007/s00705-020-04768-3. Epub 2020 Aug 10.
本文引用的文献
1
Emerging human coronaviruses--disease potential and preparedness.新出现的人类冠状病毒——疾病潜力与防范
N Engl J Med. 2012 Nov 8;367(19):1850-2. doi: 10.1056/NEJMe1212300. Epub 2012 Oct 17.
2
Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.从沙特阿拉伯一名患有肺炎的男子中分离出一种新型冠状病毒。
N Engl J Med. 2012 Nov 8;367(19):1814-20. doi: 10.1056/NEJMoa1211721. Epub 2012 Oct 17.
3
SARS veterans tackle coronavirus.非典康复者应对新冠病毒。
Nature. 2012 Oct 4;490(7418):20. doi: 10.1038/490020a.
4
Licensure of vaccines using the Animal Rule.利用“动物法则”批准疫苗。
Curr Opin Virol. 2012 Jun;2(3):353-6. doi: 10.1016/j.coviro.2012.01.004. Epub 2012 Jan 30.
5
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.接种 SARS 冠状病毒疫苗会导致在 SARS 病毒攻击时肺部免疫病理学发生。
PLoS One. 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. Epub 2012 Apr 20.
6
Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.抗严重急性呼吸综合征冠状病毒化疗的最新进展。
Future Virol. 2011 May;6(5):615-631. doi: 10.2217/fvl.11.33.
7
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.严重急性呼吸综合征冠状病毒（SARS-CoV）的刺突蛋白——疫苗和治疗药物研发的靶点。
Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9.
8
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.通过靶向刺突蛋白受体结合域的抗体对人及果子狸严重急性呼吸综合征冠状病毒进行交叉中和。
J Immunol. 2006 May 15;176(10):6085-92. doi: 10.4049/jimmunol.176.10.6085.
9
Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets.用基于安卡拉痘苗病毒的重组疫苗免疫雪貂以预防严重急性呼吸综合征与雪貂肝炎加重有关。
J Virol. 2004 Nov;78(22):12672-6. doi: 10.1128/JVI.78.22.12672-12676.2004.
10
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.严重急性呼吸综合征相关冠状病毒刺突蛋白中七肽重复序列1和2区域之间的相互作用：对病毒融合机制的影响及融合抑制剂的鉴定
Lancet. 2004 Mar 20;363(9413):938-47. doi: 10.1016/S0140-6736(04)15788-7.
Zotero 插件